AEFI reported to Chile's National Center for Pharmacovigilance (CNFV) since the start of the vaccination campaign in the six-to-eleven-year-old age group with inactivated SARS-CoV-2 vaccine (CoronaVac)


Between the start of the vaccination campaign on 13 September, and 7 October 2021, 643,204 doses of CoronaVac vaccine were administered in children between the ages of 6 and 11. The CNFV database recorded 71 reports of AEFI in this age group during the period. Of these, the CoronaVac vaccine was determined to be the suspected cause of 66 reported cases (representing 0.011% of total doses administered); in six cases the vaccine manufacturer was not identified.  

Of reported AEFI, 42.7% were in women and 57.3% in men. Four cases were reported as severe (5.6% of the total), including one case of acute disseminated encephalomyelitis, one seizure, one case of synovitis/arthralgia, and one case of anaphylaxis. 

The 71 reported cases included 51 different adverse events, for a total of 157 events. The 10 most commonly reported events were vomiting (13), pruritus and erythema at the injection site (12), headache and injection-site pain (11), fever (8), urticaria (7), and seizures, syncope, and malaise (6). AEFI continue to be closely monitored.


Source: ISP. ESAVI reportados al Centro Nacional de Farmacovigilancia (CNFV) desde el inicio de la campaña de vacunación en el grupo etario de 6 a 11 años con la vacuna SARS-CoV-2 inactivada (CoronaVac) en Chile. Available at:


At present there are no additional updates to the most recent bulletin on conclusive analyses of AEFI.

  • Share: